Mar. 17 at 12:45 PM
Cantor🏁
$TENX and said it sees 2-3X move if LEVEL hits Stat Sig and cut in ½ or worse on failure.
$TECX $MRK $BAYRY - AZN LLY
$CYTK
Cantor said::We are initiating coverage of Tenax Therapeutics (TENX) with an Overweight rating and a
$35 price ahead the pivotal LEVEL Phase 3 readout of TNX-103 (oral levosimendan) in PH-HFpEF expected in 3Q26.
TENX is still relatively under the radar with a ~
$1B fully diluted market cap, despite having a Phase 3 readout in PH-HFpEF coming in 3Q26.
If LEVEL hits and is stat sig (p<0.05), we think the stock could move 2-3x.
This is a high-risk, high-reward setup into the data. The setup cuts both ways: if LEVEL fails, the stock could get cut in half (or worse).
